There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

There is a connection between alcohol and anxiety the day after you drink for many reasons, even if you’ve not been diagnosed ...

Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

Tempero Bio was created in 2020 by the venture firm Aditum Bio to advance the clinical development of a portfolio of potent, ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...